Medication Management of Antipsychotic-Induced Weight Gain in Children and Teens

Topics: body mass index BMI | GLP-1 Agonists | Metformin | Second Generation Antipsychotics (SGAs) | Topiramate | Weight gain

Of approximately one million US children and adolescents, roughly 1% are prescribed second-generation antipsychotics (SGAs). These medications routinely breach the FDA’s level of concern of >7% body weight gain. The worst offenders are olanzapine, quetiapine, and risperidone; lurasidone and ziprasidone are of less concern (Maayan L and Correll CU,

Quetiapine vs First-Generation Antipsychotics for Aggression

Topics: Agitation | Emergency Department | First Generation Antipsychotics (FGAs) | Quetiapine | Second Generation Antipsychotics (SGAs)

REVIEW OF: Yip L et al,  J Child Adolesc Psychopharmacol 2020;30(9):534–541 Acute agitation and aggression can lead to injury in the pediatric emergency department setting. Unfortunately, efficacy data for pharmacologic treatments are sparse. Most clinicians choose first-generation antipsychotics (FGA) over second-generation antipsychotics (SG

Raising the Bar in Schizophrenia Treatment

Topics: Clozapine | Negative Symptoms | Psychosis | Schizophrenia | Second Generation Antipsychotics (SGAs)

TCPR: Antipsychotics are the standard of care in schizophrenia, but what can we do beyond that? Dr. Miller: Several things come to mind. Therapeutic alliance, addressing the full symptom picture, and greater use of clozapine in treatment-resistant cases. TCPR: Let’s start with therapeutic alliance. Dr. Miller: Nonadherence with medications is the

Lumateperone in Bipolar Depression

Topics: Bipolar Depression | Bipolar Disorder | Bipolar II | Lumateperone | Second Generation Antipsychotics (SGAs)

REVIEW OF: Calabrese JR et al, Am J Psychiatry 2021. Epub ahead of print STUDY TYPE: Randomized, placebo-controlled trial In 2019, lumateperone (Caplyta) became the 13th atypical antipsychotic with FDA approval in schizophrenia. Compared to other atypicals, it is relatively well tolerated, with low rates of akathisia and metabolic side effects. On

A Novel Treatment for Methamphetamine Use Disorder

Topics: Bipolar Depression | Bipolar Disorder | Bipolar II | Lumateperone | Second Generation Antipsychotics (SGAs)

REVIEW OF: Trivedi MH et al, N Engl J Med 2021;384(2):140–153 STUDY TYPE: Randomized, double-blind, placebo-controlled trial with sequential parallel comparison design Methamphetamine use disorder is an increasing cause of overdose deaths in the US. Pharmacologic options are scarce, but pilot studies suggest that bupropion and naltrexone may be

Sleepwalking on Antipsychotics and Lithium

Topics: Antipsychotics | Lithium | Second Generation Antipsychotics (SGAs) | Side Effects | Sleep | Sleep Disorders | Somnambulism

REVIEW OF: Gouverneur A et al, Br J Clin Pharmacol 2021;87:3971–3977 STUDY TYPE: Retrospective analysis Sleepwalking and sleep-eating are common parasomnias, also known as somnambulism and sleep-related eating disorder. Both can be side effects of benzos, z-hypnotics, and—rarely—antidepressants. This review looked at parasomnias’ association w